[Dermal and systemic side effects of fluocortin butylester. Comparative skin tearing experiments with active principles from commercial preparations].
Different concentrations of butyl 6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3,20-dioxo-1,4-pregnadien-21-oate (fluocortin butylester FCB, Vaspit) and of clobetasone-17-butyrate, clobetasole-17-propionate and hydrocortisone-17-butyrate have been administered topically in order to investigate dermal and systemic side effects. It could be shown that FCB exhibits by far the least side effects. A specially devised apparatus covering the site of substance application, guaranteed an exclusive dermal absorption. Side effects, therefore, cannot be ascribed to oral ingestion of the drugs.
D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002990:Clobetasol / Q000494:pharmacology; D005448:Fluocortolone / Q000031:analogs & derivatives / Q000494:pharmacology*; D006854:Hydrocortisone; D007668:Kidney / Q000187:drug effects; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011244:Pregnadienediols / Q000494:pharmacology*; D051381:Rats; D012867:Skin / Q000033:anatomy & histology; D012879:Skin Physiological Phenomena; D013154:Spleen / Q000187:drug effects; D013718:Tensile Strength / Q000187:drug effects; D013950:Thymus Gland / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D005448:Fluocortolone; D002990:Clobetasol; D006854:Hydrocortisone
Dermale und systemische Nebenwirkungen von Fluocortin-butylester (FCB). Hautreissversuche im Vergleich mit Wirkstoffen aus Handelspräparaten.